Osteoarthritis   |  Psoriatic Arthritis 

Meetings may look a little different this year, but our commitment to providing you with an engaging educational experience hasn’t changed. It’s always a challenge to coordinate the various sessions you’d like to attend at each meeting, so we developed new CMEO Breakfast Briefings to ensure you’re getting the key takeaways on the most recent data.

Watch the Breakfast Briefingss on osteoarthritis and psoriatic arthritis, hosted by Dr. Allan Gibofsky, to hear short 3-to-5-minute overviews of the best posters presented at #ACR2020, as well as insights on the results and why they matter to clinical practice.

Osteoarthritis

Osteoarthritis Breakfast Briefing #1

Abstract Number: 0140
Conaghan PG, Dworkin R, Schnitzer T, et al.
Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-to-Severe Osteoarthritis

Osteoarthritis Breakfast Briefing #2

Abstract Number: 0708
Denise Baldock and Casey Zhang
Differences in Treating Knee Osteoarthritis by Clinician Specialty

Osteoarthritis Breakfast Briefing #3

Abstract Number: 1482
Carrino J, McAlindon T, Vigno E, et al.
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis

Osteoarthritis Breakfast Briefing #4

Abstract Number: 1640
Schnitzer T, Berenbaum F, Conaghan PG, et al.
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab:
Pooled Analysis from International Studies

Osteoarthritis Breakfast Briefing #5

Abstract Number: 1641
Hunter D, Neogi T, Churchill M, et al.
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab:
Results from a 56-Week Randomized NSAID-Controlled Study

Osteoarthritis Breakfast Briefing #6

Abstract Number: 1643
Schnitzer T, Berenbaum F, Davignon I, et al.
Evaluating Analgesic Response to Subcutaneous Tanezumabin Patients with Inadequate Treatment Response to Other Analgesics Based on Daily E-pain Diaries:
A Pooled Analysis of 2 Randomized, Placebo-controlled Studies
Psoriatic Arthritis

Psoriatic Arthritis Breakfast Briefing #1

Abstract Number: 0320

Gazitt T, Elhija MA, Haddad A, et al.
Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients

Psoriatic Arthritis Breakfast Briefing #2

Abstract Number: 0308
Karmacharya P, Wright K, Achenbach S J, et al.
Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study
_________________________________________________________________________
Abstract Number: 0309
Karmacharya P, Wright K, Achenbach S J, et al.
Diagnostic Delay in Psoriatic Arthritis: A Population Based Study

Psoriatic Arthritis Breakfast Briefing #3

Abstract Number: 0619
Sharma N, Girardi N, Wong K
Pharmacist Intervention: Reducing Insurance Denials of Specialty Medications

Psoriatic Arthritis Breakfast Briefing #4

Abstract Number: L03
Mease P, Deodhar A, van der Heijde D, et al.
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: 
Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial 

Psoriatic Arthritis Breakfast Briefing #5

Abstract Number: 0329
Ogdie A, Hwang M, Veeranki P, et al.
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis

Psoriatic Arthritis Breakfast Briefing #6

Abstract Number: 0336
Gossec L, Walsh J, Michau K, et al.
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe